Education
About Us
Working with TipRanks
Follow Us
Nailesh Bhatt Insider Profile
4 Followers
Nailesh Bhatt, Director at Sonnet BioTherapeutics Holdings, holds 42.87K shares in Hyperliquid Strategies Inc (Ticker: PURR), holds 0.00 shares in Sonnet BioTherapeutics Holdings (Ticker: SONN).
Nailesh Bhatt Sonnet BioTherapeutics Holdings (SONN)Director
Sonnet BioTherapeutics Holdings (SONN)
Director
Not Ranked
Nailesh Bhatt has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Roles
Director
Roles that Nailesh Bhatt holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Nailesh Bhatt
Nailesh Bhatt's Trading History
Sonnet BioTherapeutics Holdings
Dec 03, 2025
―
Uninformative Sell
―
$0.00
Hyperliquid Strategies Inc
Feb 11, 2026
Director
Uninformative Buy
―
$208.35K
List of latest transactions for each holding click on a transaction to see Nailesh Bhatt's performance on stock
You May Also Like
Nailesh Bhatt insider profile FAQ
What is the percentage of profitable transactions made by Nailesh Bhatt?
The percentage of profitable transactions made by Nailesh Bhatt is ―.
What is the average return per transaction made by Nailesh Bhatt?
The average return per transaction made by Nailesh Bhatt is ―.
What stocks does Nailesh Bhatt hold?
Nailesh Bhatt holds: SONN, PURR stocks.
What was Nailesh Bhatt’s latest transaction?
Nailesh Bhatt latest transaction was an Uninformative Buy of ―.
What was Nailesh Bhatt's most profitable transaction?
Nailesh Bhatt’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Nailesh Bhatt's role in Sonnet BioTherapeutics Holdings?
Nailesh Bhatt's role in Sonnet BioTherapeutics Holdings is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.